Voyager Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Voyager Therapeutics, Inc. (VYGR) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $20.66 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-09
- Voyager Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $20.66M, a 71.14% increase year-over-year.
- Voyager Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$14.14M.
- Voyager Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $6.61M.
- Voyager Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was $42.76M.
- Voyager Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $47.30M.
- Voyager Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$194.77M.
- Voyager Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$3.30M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $20.66M 10-Q · filed 2017-05-09 | $6.51M derived: sum of 2 quarters · filed 2017-05-09 | $13.12M derived: sum of 3 quarters · filed 2017-05-09 | $55.89M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-12-31 | -$14.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$7.53M derived: sum of 2 quarters · filed 2017-03-15 | $35.23M derived: sum of 3 quarters · filed 2017-03-15 | $47.30M 10-K · filed 2017-03-15 |
| 2016-09-30 | $6.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $49.37M derived: sum of 2 quarters · filed 2016-11-10 | $61.44M 10-Q · filed 2016-11-10 | -$38.13M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-06-30 | $42.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $54.83M 10-Q · filed 2016-08-11 | -$44.75M derived: sum of 3 quarters · filed 2017-05-09 | -$55.26M derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-03-31 | $12.07M 10-Q · filed 2017-05-09 | -$87.51M derived: sum of 2 quarters · filed 2017-05-09 | -$98.02M derived: sum of 3 quarters · filed 2017-05-09 | -$182.55M derived: sum of 4 quarters · filed 2017-05-09 |
| 2015-12-31 | -$99.58M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$110.09M derived: sum of 2 quarters · filed 2017-03-15 | -$194.62M derived: sum of 3 quarters · filed 2017-03-15 | -$194.77M 10-K · filed 2017-03-15 |
| 2015-09-30 | -$10.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$95.04M derived: sum of 2 quarters · filed 2016-11-10 | -$95.19M 10-Q · filed 2016-11-10 | -$96.20M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | -$84.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$84.68M 10-Q · filed 2016-08-11 | -$85.69M derived: sum of 3 quarters · filed 2017-03-15 | |
| 2015-03-31 | -$150.00K 10-Q · filed 2016-05-12 | -$1.16M derived: sum of 2 quarters · filed 2017-03-15 | ||
| 2014-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$3.30M 10-K · filed 2017-03-15 | ||
| 2014-09-30 | -$2.29M 10-Q · filed 2015-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |